本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Orchestral – a Pioneering AI Orchestrator Data Platform Built for Healthcare AUCKLAND, New Zealand, Dec. 17, 2025 /PRNewswire/ -- McCrae Tech has launched the world's first health AI orchestrator. The product, called Orchestral, is a health-native AI orchestrator data platform. It seamlessly connects diverse data sources with AI agents, workflows, and algorithms – enabling scalable, governed AI deployment across healthcare systems. "Most information technology in healthcare falls into two camps: either a big, dumb bucket of cloud data or isolated pockets of AI cleverness," said Ian McCrae, founder of McCrae Tech. "We have created something vastly different that reshapes healthcare as we know it." Orchestral integrates three core components: Health Information Platform (HIP): Ingests data from any source and delivers trusted, structured, standardized, and compliant health data. Health Agent Library (HAL): Provides a governed registry of AI building blocks for the entire health system. Health AI Tooling (HAT): Empowers data analysts and scientists to build agentic workflows, business intelligence reports, and more. "Simply swamping clinicians with more data is not the answer to improve healthcare. Extra data may contain useful insights, but these are needles in a haystack without the necessary AI tooling to extract them into human-understandable observations. "Orchestral delivers exactly that, enabling healthcare providers to harness AI's full potential. Its potential impact on global health is comparable to the transformative shifts brought about by antibiotics, modern hygiene, and other breakthrough public health innovations," says McCrae. Lucy Porter, CEO of Orchestral, highlighted the unsustainable pressures on U.S. and global health systems, including rising costs, workforce burnout, and error risks. "Right now, up to 15% of diagnoses globally are estimated to be inaccurate, delayed or wrong[1]. This has huge implications for patients and is estimated to create a financial burden equivalent to 17.5% of total healthcare expenditure in OECD nations[2]. "Everyone is turning to AI to solve these issues. But what we see today is unworkable AI chaos – pilots and point solutions with no clear path to safe, widespread deployment. "Without a dedicated health AI orchestrator, rapidly scaling AI remains virtually impossible. Orchestral fills this critical gap, serving as the trusted source of truth for models, tools, and data connections that teams rely on to deliver better care. "We're building the foundation that lets entire health ecosystems learn, adapt, and thrive in the age of agentic AI. We're here to turn the world's scattered health data into life-saving insight that's trusted, explainable, and ready when it matters most," says Porter. Orchestral has been built upon decades of clinical data storage engineering, initially within Orion Health and then, more recently, spun out into McCrae Tech as a standalone company because of the magnitude of this project. What has emerged is a genuinely world-first product, defining a new category in health technology. About McCrae Tech McCrae Tech is a 100% New Zealand-owned innovation lab from the founders of Orion Health. It builds specialist health tech designed for clinical complexity, combining three decades of experience building health software that supports millions of lives, with the speed and agility of a start-up.www.mccrae.tech About Orchestral Orchestral is the world's first health AI orchestrator and is reshaping the future of healthcare with AI. It seamlessly connects diverse data sources with AI agents, workflows, and algorithms – enabling scalable, governed AI deployment across healthcare systems. www.orchestral.co [1] The economics of diagnostic safety | OECD [2] The economics of diagnostic safety | OECD
HANGZHOU, China, Dec. 16, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients. PVAD supports the cardiac output via a percutaneously implanted pump, reduces the load of left ventricle, relieves heart failure symptoms, and bridges to transplantation or recovery. It also delivers temporary hemodynamic support during Complex Higher-risk Indicated Patients Percutaneous Coronary Intervention (CHIP PCI) procedures by augmenting cardiac output, preserving organ perfusion, and stabilizing hemodynamics for safe intervention. While over 60,000 pVAD procedures are performed globally each year, no pVAD product has been approved in China yet, underscoring the significant unmet medical need. OpusOne™ features an ultra-low profile down to 8F, external durable motor placement, and an all-new design of foldable, self-expanding impeller, capable of delivering 4–5 L/min of average flow with peak flows exceeding 7 L/min. Notably, this ultra-compact device integrates invasive blood pressure monitoring and patented perfusion purification system, enabling migration detection alerts while preventing wear particles from entering the patient's body. With high durability, enhanced reliability, OpusOne™ simplifies clinical procedures, improves patient accessibility, and emerges as a highly competitive pVAD - rivaling Abiomed's Impella, Magenta's Elevate, and Supira's pVAD systems. First-in-Human Study of OpusOne™ pVAD at SAHZU” "Enginprime's OpusOneTM exemplified a promising approach to temporary ventricular support—especially for high-risk patients who can benefit from enhanced hemodynamic stability. Co-developed by the interventional cardiologists and Enginprime, this promising solution is tailored to address unmet clinical needs." said the study's lead investigator Jian'an Wang, MD,PhD, Director of the Cardiac Center at SAHZU. "I am impressed by its ability to achieve high flow with such a low-profile design. OpusOneTM's optimization of access and positioning options increases procedural safety." Co-investigator of the study, Jun Jiang, MD, PhD, Executive Associate Director of the Department of Cardiology at SAHZU added, "We are pleased to perform the first procedure with OpusOneTM, seeing the patient's chest tightness was significantly alleviated. Its robust initial performance marks a meaningful advancement in circulatory support and great potential for expanding patient eligibility." "The development of OpusOneTM reflects our mission to bring globally competitive, exceptional performance and high reliability, cost-effective next-generation circulatory support products to patients who need them most," said the CEO of Enginprime. "We look forward to advancing this innovative device rapidly through further clinical validations." About Enginprime Medical Inc. Enginprime was established in 2023 and incubated under majority ownership by Voyagers Capital, leveraging cross-disciplinary engineering capabilities, systems integration expertise, and advanced manufacturing methodologies. OpusOne™ is the company's first flagship medical device platform and reflects Voyagers' long-term commitment to supporting breakthrough healthcare technologies. About Voyagers Capital Voyagers Capital is a leading healthcare venture capital firm focused on investing in groundbreaking biotech and medtech innovation. By leveraging our expertise and network, we partner with visionary entrepreneurs to bring transformative solutions to the global market. OpusOne™ is an investigational device, not yet approved for commercial use. For more information, please contact:media@enginprime.com; info@voyagerscap.com.
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs. Daiichi Sankyo will apply various Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to explore novel biomarkers and to potentially enrich clinical trials or to potentially support precision patient stratification for select oncology pipeline programs. "Lunit SCOPE was built to unlock hidden insights from pathology slides - quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design," said Brandon Suh, CEO of Lunit. "SCOPE uIHC is now enabling the next generation of IHC-based biomarkers. By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification. Ultimately, this means more efficient trials and better outcomes, where each patient has a greater chance of receiving the therapy that works best for them." The work will include exploratory research projects and analyses across two oncology assets across multiple types of cancer, with the potential to inform future trial designs, biomarker strategies and clinical development plans. About Lunit Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis—empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum. Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development. Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact—for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io/en.
Acquisition creates a fully integrated regional connectivity platform, enabling seamless, low-latency connectivity that supports ASEAN’s expanding digital economySINGAPORE/KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 13 December 2025 - SEAX Global (“SEAX”), a leading wholesale connectivity provider in Southeast Asia, today announced it has acquired a major stake in Interlink Telecom Public Company Limited (“ITEL”), a prominent Thai fixed network telecommunications provider. This acquisition consolidates SEAX’s presence across Malaysia, Singapore, Indonesia, and now Thailand, integrating ITEL’s nationwide fiber network infrastructure and telecommunications licences with SEAX’s regional subsea and terrestrial networks. By leveraging ITEL’s on-ground operational capabilities alongside SEAX’s cross-border reach, customers can expect faster deployment timelines, greater service flexibility, and more seamless regional connectivity. ITEL Global, a new subsidiary formed to serve international requirements from both local and major global clientele, will continue managing operations within Thailand, preserving its local expertise and market familiarity while aligning with SEAX’s broader regional strategy to deliver a network footprint with unparalleled coverage, improved reliability, and a customer-centric approach throughout Southeast Asia. Louis Teng, Group CEO of SEAX Global, said, "By bringing together our regional networks with ITEL’s deep local expertise in Thailand, we’re creating a powerful, customer-focused platform that can keep pace with the rapid digital transformation underway in ASEAN. This partnership enables us to deliver robust, low-latency connectivity solutions that meet the evolving needs of enterprises and digital ecosystems seeking seamless cross-border service." Dr. Nuttanai Anuntarumporn, Group CEO of Interlink Telecom, added, "Thailand’s digital infrastructure is evolving swiftly, and through collaboration with SEAX, we have the opportunity to become a regional seamless connectivity provider, developing and operating high-performance cross-border infrastructure connecting Thailand, Singapore, Malaysia, Indonesia, Vietnam, and Hong Kong. Together, we will jointly build and operate this infrastructure, integrate our networks, and deliver seamless regional connectivity across ASEAN.” McKinsey highlights that Southeast Asia’s digital economy is projected to grow at a compound annual growth rate of nearly 20%, fuelled by rising digital adoption across businesses and consumers, and expanding digital services including cloud computing and online payments. This surge is driving robust demand for reliable fibre connectivity and cross-border data solutions critical for digital platforms, OTT providers, and multinational enterprises. This strategic expansion creates an integrated end-to-end regional connectivity platform, improving network coverage, reliability, and service flexibility. SEAX’s SIJORI hub, covering Singapore, Johor Bahru, and Batam, complements Interlink’s Thailand network, critical as digital economy growth accelerates, especially via data centre and AI-related services. Hashtag: #SEAXGlobalThe issuer is solely responsible for the content of this announcement.SEAX GlobalSEAX Global is a privately funded, geopolitically neutral leader in Southeast Asia’s wholesale connectivity solutions. Established in 2013, SEAX specializes in submarine and terrestrial cable systems, cable landing stations, and data center colocation, providing seamless, high-performance connectivity across the region. SEAX is owned by Forbes Asia Billionaire Dato’ Dr. Low Tuck Kwong’s family, the Singapore-born Indonesian entrepreneur best known as the founder of Bayan Resources and one of Southeast Asia’s wealthiest businessmen. The company holds full operational licenses in Malaysia, Singapore, and Indonesia. These licenses uniquely allow SEAX to build and operate private fixed networks for dedicated or enterprise use. Leveraging its regulatory compliance, extensive network portfolio, and regional expertise, SEAX empowers businesses with reliable, scalable, and secure data transmission, supporting cross-border connectivity and exceptional customer service across Southeast Asia while positioning itself for continued growth and regional expansion. Interlink TelecomInterlink Telecom Public Company Limited (ITEL) is Thailand Telecommunications Network Service Provider, with a type 3 Telecommunications License from The National Broadcasting and Telecommunications Commission (NBTC). ITEL provides telecommunication services through a fiber optic network nationwide in Thailand. The company offers various services, such as MPLS IP-VPN, dark fiber, wavelength, IPLC, as well as telecommunication network installation and broadcast services. ITEL also provides data center space services, including co-location, cloud computing, and disaster recovery services. ITEL was established in 2007 and headquartered in Bangkok, Thailand. In 2024–2025, ITEL expanded into its fourth business segment in medical equipment distribution and service. Through Interlink Health Technology (IHT), the company provides medical equipment rental services, supported by skilled technicians and mobile service units for hospitals nationwide.
NEW YORK, Dec. 12, 2025 /PRNewswire/ -- The holiday season is a time for family, celebration, and cherished moments. For individuals who rely on respiratory support, maintaining energy and wellness can be a challenge amid busy schedules, colder weather, and seasonal changes. VARON highlights practical solutions to help families ensure their loved ones stay active, healthy, and engaged throughout the festive season. Supporting Respiratory Health Through the Holidays For many seniors and individuals with chronic respiratory conditions, having access to reliable oxygen therapy is essential. VARON oxygen concentrators provide reliable oxygen solution both at home and on the go, helping users maintain stamina, comfort, and independence. Families looking for oxygen concentrators for sale this season can explore devices designed to meet different lifestyles and activity levels. For this year's holiday specials, VARON is including a $30 gift card with every oxygen concentrator purchase, alongside a 20% sitewide discount and select models marked down by up to 40%. The added savings allow families to choose high-quality oxygen support while setting aside extra resources for holiday needs, travel, or caregiving essentials. Strengthening Community Wellness Through the FOSSVI Partnership In the spirit of giving, VARON has extended its holiday commitment beyond individual households—joining hands with FOSSVI (Fundación Obras Sociales de San Vicente, IAP) to strengthen respiratory care for some of Mexico's most vulnerable communities. Through this collaboration, VARON donated Serene 5 home oxygen concentrators to elderly residents and Sisters of the Hogar San Vicente and Santa Luisa Annex. These homes serve individuals who often face chronic respiratory challenges, and access to dependable oxygen therapy is essential to their comfort and daily well-being. The equipment provided by VARON is already helping residents breathe more easily, rest more peacefully, and experience a noticeable improvement in their overall quality of life. This partnership reflects VARON's belief that wellness should be accessible to every family and every community—not only during the holiday season, but throughout the year. The impactful collaboration with FOSSVI demonstrates how community support, combined with advanced respiratory technology, can transform lives and bring renewed comfort to those who have spent decades in service to others. For more information about this partnership visit: VARON Mexico A Thoughtful Holiday Gift VARON has partnered with Kokorosa Studio to make wellness and creativity part of the same festive experience. For any purchase over $500, customers receive a free craft cutting machine, ideal for creating holiday cards, decorations, scrapbooks, and small DIY gifts. This combination allows families to integrate health and creativity, creating opportunities for shared moments with grandchildren or loved ones. Best-Selling VARON Oxygen Concentrators for Holiday Wellness VARON offers a range of home and portable oxygen concentrator machine to fit different lifestyles: Serene 3L Premium Home Oxygen Concentrator – A reliable home oxygen concentrator, delivering 93 ± 3% oxygen at 1–3 L/min. Features include quiet operation, nebulizer function, and a large humidification bottle for comfortable therapy. Serene 5L Home Oxygen Concentrator – Provides 93 ± 3% medical-grade oxygen at 0.5–5 L/min, FDA-approved, low-noise, and energy-efficient. Ideal for families seeking dependable home oxygen concentrators. VP-8G Portable Oxygen Concentrator – Lightweight (4.37 lbs) and compact, delivering 1–8 L/min pulse flow. It allows users to enjoy mobility, indoor or outdoor activity, and safe travel during the holidays. VP-6 Portable Oxygen Concentrator – Continuous flow from 1–6 L/min, with a built-in nebulizer and replaceable battery. Designed for everyday use, it provides steady oxygen support while promoting confidence and independence. These VARON oxygen concentrators are chosen not only for their reliability but also for their ease of use, portability, and ability to help loved ones maintain an active lifestyle. Order in Time for the Holidays To ensure delivery before Christmas, VARON encourages customers to place their orders by December 20, 2025. Ordering early ensures both timely holiday gifting and uninterrupted respiratory support, giving recipients the comfort and confidence to fully enjoy the season. Wellness, Comfort, and Love VARON's holiday offerings combine health, functionality, and family engagement. By supporting respiratory wellness and providing tools for creativity and shared experiences, VARON helps families celebrate a season that is both safe and joyful. With the right support, seniors and individuals with respiratory needs can participate fully in holiday traditions while staying healthy and energized. For more information and guidance on oxygen support this holiday season, visit VARON website. Media Contact: VARON Oxygen Solutions Email: official@varoninc.com Website: www.varoninc.com
SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group, framed that vision with a timely question: "Agent Radiologist: Are We There Yet?" The company invited attendees to experience a new generation of AI agents capable of understanding, reasoning, and acting across the entire care pathway, bringing more precise and accessible healthcare within reach. Digital Transformation in Action: Medical Imaging Powered by AI Agents The question "Agent Radiologist: Are We There Yet?" was inspired by uAI Insight, a next-generation Imaging-to-Report AI agent making its North American debut. Drawing strong interest from visitors around the world, uAI Insight demonstrated how AI can elevate diagnostic workflows by integrating clinical reasoning directly into reporting. Powered by UII's multimodal large models, integrating language, vision, and speech, the system recognizes complex patterns, correlates key findings, and generates structured reports with clarity and precision. Many attendees expressed strong interest in future collaboration with UII. Within uAI Insight, the uAI Agent for Chest CT Reporting demonstrated the ability of detecting 73 thoracic diseases from a single scan with an average AUC of 95%. The uAI Agent for Brain MRI Reporting identified 47 neurological conditions from one scan. Together, these tools signal the next phase of medical AI as the field shifts from task automation toward intelligent human-AI partnership. RSNA 2025 also marked the debut of the uAI Agent for Ultrasound, an embodied AI robotic-arm system that integrates autonomous scanning with AI-assisted diagnosis. Interpreting visual, tactile, and pressure cues in real time, the agent adjusted probe position and force with precision, offering a gentler and more personalized patient experience. A Unified Ecosystem of Intelligence: "Digitelligent Hospital" of Tomorrow Across the booth, visitors saw how AI agents collaborate throughout the clinical workflow. uAI Avatar, an intelligent medical assistant, guided attendees through an end-to-end pre-diagnosis journey using natural conversation. Meanwhile, the uAI Agent for Hospital Management monitored imaging and reporting quality, assessed equipment performance, and transformed complex operational data into actionable insights. These agents spanned diagnostic imaging, surgical care, patient services, hospital operations, and clinical research, illustrating how AI can elevate care at every stage of the patient journey. Expanding on these AI-driven interactions, UII introduced the concept of the "Digitelligent Hospital". Built on UII's multimodal medical large models, trained through years of clinical collaboration and supported by United Imaging's comprehensive technology portfolio, this vision reflects an evolving ecosystem where digital and intelligent technologies reshape infrastructure, software, and operations. These models empower AI agents to analyze, reason, and make informed decisions, while embodied AI brings that intelligence into real-world tasks and natural human interaction. The result is a hospital that continuously learns, adapts, and evolves across all stages of care. RSNA 2025 underscored a pivotal shift: medical AI is moving beyond traditional algorithms toward collaborative, autonomous AI agents that respond, adapt, and connect. With its rapidly expanding ecosystem, UII is leading the industrial innovation towards a more intelligent, virtualized, comprehensive, and personalized era of healthcare. (Products and features referenced may not be available in all countries, and future availability cannot be guaranteed. Not all AI applications presented are CE-marked or FDA-cleared.)
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
